AIM Biotech

Executive Summary

AIM Biotech is a Singapore-based biotechnology company pioneering human-relevant microphysiological systems (MPS) for drug discovery and precision medicine. Its flagship platforms, idenTx and organiX, integrate standardized primary or iPSC-derived cells with 3D microfluidic chips to create scalable 'BioAvatars' that recapitulate human tissue physiology, enabling more predictive preclinical testing. The company serves pharmaceutical and biotech clients with both off-the-shelf kits and custom contract research services across oncology, immuno-oncology, vascular biology, and neurobiology. Founded in 2020, AIM Biotech addresses the growing need for alternatives to animal models, leveraging Singapore's strong biomedical ecosystem to accelerate the adoption of organ-on-a-chip technology in drug development pipelines.

Upcoming Catalysts (preview)

• Q3 2026Major pharma partnership for oncology drug screening70% success
• Q3 2026Launch of new neurobiology organ-on-a-chip model80% success
• Q4 2026Series B funding round to scale commercialization65% success